Enanta Pharmaceuticals
ENTA
111 hedge funds and large institutions have $220M invested in Enanta Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 31 reducing their positions, and 6 closing their positions.
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
26% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 31
11% more funds holding
Funds holding: 100 → 111 (+11)
10% more call options, than puts
Call options by funds: $54K | Put options by funds: $49K
4.31% less ownership
Funds ownership: 104.49% → 100.19% (-4.3%)
23% less capital invested
Capital invested by funds: $287M → $220M (-$67.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.9M |
| 2 |
KAM
Krensavage Asset Management
New York
|
+$3.23M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.71M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.49M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
-$9.42M |
| 2 |
Morgan Stanley
New York
|
-$4.62M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$4.37M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$4.03M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.7M |
ENTA Hedge Fund Activity: Q3 2024 in Review
111 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2024, worth a combined $220M — down 23% from $287M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ENTA positions and 6 closed out — a net gain of 11 holders — while 39 added to existing stakes and 31 trimmed.
The largest buyer was Ameriprise, adding an estimated $3.9M. The largest seller was Caligan Partners, cutting an estimated $9.42M.
- 111 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2024, up from 100 in Q2 2024.
- Funds reported $220M of Enanta Pharmaceuticals stock for Q3 2024, down 23% quarter-over-quarter.
- 17 funds opened new Enanta Pharmaceuticals positions in Q3 2024 and 6 closed out, a net change of +11 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2024 was Ameriprise, an estimated $3.9M added.
- The largest Enanta Pharmaceuticals seller in Q3 2024 was Caligan Partners, an estimated $9.42M sold.
Based on aggregated 13F filings for Q3 2024.